Rathbones Group PLC Sells 38,606 Shares of Guardant Health, Inc. $GH

Rathbones Group PLC decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 18.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 166,507 shares of the company’s stock after selling 38,606 shares during the quarter. Rathbones Group PLC’s holdings in Guardant Health were worth $15,380,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after purchasing an additional 25,831 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Guardant Health during the 1st quarter worth about $274,000. Sei Investments Co. grew its position in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after buying an additional 10,538 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Guardant Health by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after acquiring an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Guardant Health by 56.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after acquiring an additional 40,209 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on GH. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Friday, July 17th. TD Cowen increased their target price on shares of Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Friday. Guggenheim lifted their price target on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Finally, BTIG Research boosted their price target on shares of Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $179.82.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CFO Michael Brian Bell sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $128.62, for a total transaction of $257,240.00. Following the sale, the chief financial officer directly owned 47,509 shares in the company, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Myrtle S. Potter sold 1,556 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the sale, the director owned 20,971 shares in the company, valued at $2,750,556.36. This trade represents a 6.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 708,565 shares of company stock worth $90,556,597 in the last quarter. Company insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

NASDAQ GH opened at $158.83 on Tuesday. Guardant Health, Inc. has a one year low of $41.19 and a one year high of $176.58. The firm has a market cap of $21.31 billion, a P/E ratio of -45.51 and a beta of 1.60. The stock’s 50-day moving average is $144.24 and its 200-day moving average is $113.78.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.